Exploring the microbiome in patients with cutaneous T cell lymphoma
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
This study looks at the gut bacteria of people with cutaneous T cell lymphoma to see how it compares to healthy individuals and if it can help us understand the disease better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | Northwestern University Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT03932279 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the microbiome of patients diagnosed with cutaneous T cell lymphoma and compare it to that of age and sex-matched healthy controls. The study will include various groups of patients with different stages of cutaneous T cell lymphoma, as well as individuals with related skin conditions and healthy participants. By analyzing the microbiome, researchers hope to uncover potential differences that could provide insights into the disease's pathology and treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-89 with cutaneous T cell lymphoma at various stages, as well as individuals with related skin conditions and healthy controls.
Not a fit: Patients outside the age range of 18-89 or those with conditions not specified in the eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the microbiome's role in cutaneous T cell lymphoma, potentially leading to new therapeutic strategies.
How similar studies have performed: While the specific approach of characterizing the microbiome in cutaneous T cell lymphoma is novel, similar studies in other cancers have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group 1: Patients with stage IA-IIA cutaneous T cell lymphoma * Group 2: Patients with stage IIB and above cutaneous T cell lymphoma * Group 3: Patients with CD30+ lymphoproliferative disorder including lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma * Group 4: Patients with plaque psoriasis with BSA\>5% on routine phototherapy per standard of care * Group 5: Patients with moderate to severe atopic dermatitis on routine bleach bath therapy per standard of care * Group 6: Healthy individuals without the above skin conditions, similar age and sex distribution to the patients with cutaneous T cell lymphoma * All Groups: subjects who are age 18-89 years of age at time of enrollment * All Groups: Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443). Exclusion Criteria: * All Groups: Subjects who are younger than 18 years of age or older than 90 years of age * All Groups: Subjects who are unable to give consent * Patients currently on systemic antibiotics or recent (within past 4 weeks) exposure to systemic antibiotics * We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.
Where this trial is running
Chicago, Illinois
- Northwestern University — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Alan Zhou, MD — Northwestern University
- Study coordinator: Dermatology CTU
- Email: NUderm-research@northwestern.edu
- Phone: 312-503-5944
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.